Advertisement
Advertisement

Read Now: TheBodyPRO.com Covers AIDS 2014

Recombination Dynamics in Case of MDR HIV Sub-Type D Following Superinfection With Wild-Type HIV Sub-Type B

July/August 2012

While research into reinfection is largely driven by expanding number of case studies, Koning and colleagues from the UK described the dynamics of reinfection with wild-type virus, using single genome sequencing (SGS) in both plasma and semen samples.

Sequential plasmas sampling was performed over 87 weeks, with one semen sample, in a treatment naive patient. The initial sub-type D sample at diagnosis showed RT mutations at D67N, K70R, A98G, K101E, Y181C, G190A, T215L and K219E which was maintained at week 34. At 54 weeks, 18/25 genomes remained similar to baseline, with 1/25 wild-type sub-type B and 3/25 recombinant B/D sub-types with variable resistance.

At weeks 85 and 87, only 2/43 genomes related to the baseline sample, 3/43 were drug-sensitive sub-type B and 39/43 were B/D recombinants, only one of which maintain drug resistant mutations.

The single semen sample at week 87 showed 18/21 of genomes sampled to be sub-type B, and the remaining three B/D recombinants all to be drug sensitive.

No data was presented on subsequent patient treatment history.


Reference

Koning FA et al. Dynamics of recombination in HIV-1 following superinfection described using single genome sequencing. 20th Intl Drug Resistance Workshop, 5-9 June 2012, Sitges. Abstract 62. Antiviral Therapy 2012: 17 Suppl 1:A77.




This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement